← Evidence map

TrialDermatology (Basel, Switzerland)2025

Lebrikizumab Improved Itch Symptoms and Reduced Itch Interference on Sleep over 52 Weeks in Patients with Moderate-to-Severe Atopic Dermatitis in Two Phase 3 Trials.

Gil Yosipovitch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Lebrikizumab Improved Itch Symptoms and Reduced Itch Interference on Sleep over 52 Weeks in Patients with Moderate-to-Severe Atopic Dermatitis in Two Phase 3 Trials. | OpenQuestion